- In January 2025, Abbott, announced the launch of its next-generation immunoassay analyzer, the Alinity M, designed to enhance lab efficiency and testing speed. The system features advanced automation capabilities, high throughput, and a broad assay menu, supporting a wide range of diagnostic tests, including infectious disease, oncology, and genetic testing, making it a critical tool for modern clinical laboratories
- In October 2024, ARUP Laboratories, introduced its AI-powered molecular diagnostic platform, designed to improve the accuracy and speed of complex genetic testing. This platform integrates deep learning algorithms and advanced molecular techniques, providing faster turnaround times and highly precise diagnostic results for personalized medicine
- In September 2024, OPKO Health, Inc. announced the expansion of its BioReference Laboratories network, enhancing its diagnostic capabilities with a focus on cancer genomics and personalized healthcare. The expansion includes the addition of advanced genetic testing and precision oncology services, supporting better patient outcomes and targeted treatment strategies
- In September 2024, Bioscientia Healthcare GmbH, a leading provider of clinical laboratory services in Europe, launched its innovative microbiome analysis platform, designed to provide comprehensive insights into gut health and disease prevention. The platform uses next-generation sequencing (NGS) and advanced bioinformatics to deliver personalized health insights
- In September 2024, Charles River Laboratories, a major player in preclinical and clinical laboratory services, introduced its new bioanalytical testing services for cell and gene therapies, aimed at supporting biopharmaceutical companies in the development of next-generation therapies. This expansion is expected to accelerate the development of personalized medicines and advanced biologics
